IL4-ECs: QUICK FACTS

  • IL-4R target over-expressed by 20 cancers afflicting over 1 million patients every year
  • Targets cancer using a multi-pronged approach
  • Disrupts the immunosuppressive tumor micro environment (TME)
  • Restores Th1>>Th2 balance
  • Purges Myeloid Derived Suppressor Cells (MDSCs)
  • Depletes Tumor Associated Macrophages (TAMs)
  • Inhibits growth of quiescent Cancer Stem Cells (CSCs)
  • Apoptosis is independent of cancer cell growth rate
  • Highly potent as a monotherapy in the picomolar range
  • Synergistic with chemotherapy in the femtomolar range
  • Chemo and radiation resistant cancers are sensitive; No resistance mechanism
  • Payload is potent within the cytoplasm, but inactive outside the target cell
  • Payload must be linked to Superkine™ for cell entry
  • Intracellular furins, expressed by tumor cells, required for toxin activation
  • Selectively target Type I (blood tumors) or Type II (solid tumors) IL4Rs
  • Wide therapeutic window
  • Relatively simple to manufacture
  • Homogenous, stable and mono-disperse fusion proteins
  • Fully human fusions likely to be non-immunogenic
Top